RxDoctor Payments Data

Frood Eelani, DO

Internal Medicine · Fort Worth, TXNPI 1417977703

Payments from drug & device makers

$808in general payments, 2019–2025

Across 49 payments — averaging $16.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$256
  • Novo Nordisk$186
  • Amarin Pharma, Inc.$104
  • AbbVie$79
  • Pfizer$43
  • Johnson & Johnson$39
  • plus $100 from 4 others

What the payments were for

  • Food & beverage$808100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$808 in reported general payments places this provider in the 65th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$162,921
Medicare patients
359
Services billed
1,666

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban94$120,160
MounjaroTirzepatide77$82,536
JardianceEmpagliflozin64$76,608
OzempicSemaglutide37$47,456
XareltoRivaroxaban30$35,494
FarxigaDapagliflozin Propanediol24$27,068
LinzessLinaclotide12$21,680
RexultiBrexpiprazole12$14,136
Tresiba Flextouch U-100Insulin Degludec18$10,897
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog23$9,751
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog26$8,969
BrilintaTicagrelor17$7,144
Icosapent Ethyl13$6,642
Humulin N KwikpenInsulin Nph Human Isophane14$4,876
LantusInsulin Glargine,hum.Rec.Anlog11$4,779

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$43$120,16094 claims
Lilly USA, LLCMounjaro$256$82,53677 claims
Boehringer IngelheimJardiance$36$76,60864 claims
Novo NordiskOzempic$186$47,45637 claims
Johnson & JohnsonXarelto$39$35,49430 claims
AbbVieLinzess$79$21,68012 claims
Otsuka America Pharmaceutical, Inc.Rexulti$22$14,13612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Fort Worth

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →